EP300 and colorectal cancer: On the other hand, EP300 overexpression has been described to be associated with poorer outcome and higher aggressiveness in several tumors including HNSCC and cutaneous squamous cell carcinomas, colorectal cancers and hepatocellular carcinoma35–38.